Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies.
about
Comparative modelling of protein structure and its impact on microbial cell factories.A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coliPathophysiology of the antiphospholipid syndromeDomain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesChemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I.New therapeutic targets for the antiphospholipid syndrome.Autoantibodies directed against domain I of beta2-glycoprotein I.Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosisβ2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies.Antiphospholipid Syndrome during pregnancy: the state of the artLJP 1082: a toleragen for Hughes syndrome.The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion InjuryMeasuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndromeMechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism.Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.The role of LRP8 (ApoER2') in the pathophysiology of the antiphospholipid syndrome.β(2) -Glycoprotein I: evolution, structure and function.Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I.Antibodies against domain I of β2-glycoprotein I: the one and only?Anti-β2-glycoprotein I antibodies.New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies.Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation.Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues.Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome.Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools.Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenesPEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome
P2860
Q24811118-5B5730CA-63B9-427F-ABDF-4C2E21534BADQ25255895-97B637C8-A42B-4C7A-AD8A-3E845B3CFBC7Q28267421-8E905106-B493-4811-A4AC-308620A5D895Q28291393-5A0B0F1A-209B-45F7-AE77-A4F4A063F823Q30497721-146F21DA-27BF-42A9-A42C-09CC7B212800Q33403225-B5394874-E077-42B7-8245-EE6DBCEFD289Q33794973-0A7BC016-32A9-41BA-AB05-EC5814FEB86DQ33844273-25CF5BFF-832E-4CF9-A3AD-6ED9D624FA7EQ34140319-88BEE648-155C-4CB2-B9EA-F4112EC60AE3Q34467454-DD1BD8E0-4E87-4AB4-B83B-F59B2723D75EQ34949493-EA8E53D7-681F-46B4-A886-EA986170184EQ35214636-F0236EEC-C071-42B6-8B98-E70F3E5EF1A2Q35584256-0765538D-756D-4A8C-AF7F-BC8F5B46C1F5Q35709692-A276F24B-4976-4DCF-B2D6-A9E4D117DB60Q35756040-10489FC5-8620-47F5-B134-D9E266D98B76Q35824487-250A39B1-7B77-406D-9BE5-89310FA6DA89Q35974974-E7BD2483-0BD6-49E2-AA0D-81A9714DBDAFQ36037794-E141D8DA-D7FC-4345-AE20-48812896D95AQ36225236-D77A58AA-9BC6-4A5E-866E-6CA8DE68F24EQ36774243-28667807-6D00-4593-98DD-0829281619C0Q37088895-0B1840B9-AA6A-4AEA-AA1C-A2A606E4DB80Q37095385-077DA412-87F6-4FC0-8F87-A533CBA7B1A3Q37721602-230C31F1-FE42-450F-8E63-18D2729AC7D3Q37871051-E97F46DC-D41B-478D-9D15-F207EFC04267Q37903952-235F3172-9691-42FE-B13C-E678388D57CEQ38013590-4891BE85-653B-4419-9376-B463D7379ACFQ38108396-B0310F31-7200-498D-A0FF-FC12536C7ED3Q38175886-A40DDD47-8A2B-4899-97FF-DA28A2229636Q38305221-17A7F28E-6B6B-4AEB-87DB-C2D63B53324BQ38678297-DD66F75D-C035-42F7-B71E-5A361C1A04A4Q39716593-83EC1DA7-A8F0-49A6-9248-420A39DF3576Q40649226-14B9EC32-0FE2-4643-A346-75CD19B28003Q46373484-F527CC56-BBED-4437-840E-F987467DAA54Q47998109-75E7D649-A2EE-4810-8328-2ECBAAD8D043Q49042052-010CBA9B-3415-45AF-AD0A-27F9BA581456Q57983447-BF582F24-2AA6-43D2-AD9B-993048AF159CQ58580417-D6D1E263-44A4-4C41-A4CE-DA63799D6DA1
P2860
Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Use of single point mutations ...... tiphospholipid autoantibodies.
@en
Use of single point mutations ...... tiphospholipid autoantibodies.
@nl
type
label
Use of single point mutations ...... tiphospholipid autoantibodies.
@en
Use of single point mutations ...... tiphospholipid autoantibodies.
@nl
prefLabel
Use of single point mutations ...... tiphospholipid autoantibodies.
@en
Use of single point mutations ...... tiphospholipid autoantibodies.
@nl
P2093
P1476
Use of single point mutations ...... tiphospholipid autoantibodies.
@en
P2093
David M Marquis
Edward J Victoria
G Michael Iverson
Keith A Cockerill
Matthew D Linnik
Stephen Reddel
Steven A Krilis
Ying-Xia Wang
P304
P356
10.4049/JIMMUNOL.169.12.7097
P407
P577
2002-12-01T00:00:00Z